Elanco Q4 adjusted EPS $0.14, revenue $1.02B; FY 2025 guidance reflects FX headwinds

Elanco Animal Health Inc

2024-FY EPS reported $0.68 revenue$4,439,000,000

Q4 2024 revenue $1,020M (-1% reported, +4% organic CC); adjusted EPS $0.14 (vs $0.08); adjusted EBITDA $177M (17.4% margin).
FY 2024 revenue $4,439M (flat reported, +3% organic CC); adjusted EPS $0.91 (vs $0.89); innovation revenue $461M (beat target).
FY 2025 guidance: revenue $4,445-4,510M; adjusted EPS $0.80-0.86; adjusted EBITDA $830-870M; mid-single-digit organic CC growth.
2025 innovation revenue target raised to $640-720M; net leverage 4.3x; expects FX headwind of $110M to revenue, $45M to EBITDA.
Q1 2025 guidance: revenue $1,155-1,180M; adjusted EPS $0.29-0.34; adjusted EBITDA $240-260M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.